Source: Trials [Trials] 2025 Mar 19; Vol. 26 (1), pp. 97. Date of Electronic Publication: 2025 Mar 19.Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

TAD-SIE: sample size estimation for clinical randomized controlled trials using a Trend-Adaptive Design with a Synthetic-Intervention-Based Estimator.

Authors : Lala S; Department of Electrical and Computer Engineering, Princeton University, Princeton, 08544, NJ, USA. .; Jha NK

Subjects: Randomized Controlled Trials as Topic*/Randomized Controlled Trials as Topic*/Randomized Controlled Trials as Topic*/methods ; Clinical Trials, Phase III as Topic*/Clinical Trials, Phase III as Topic*/Clinical Trials, Phase III as Topic*/methods ; Algorithms*

Source: Trials [Trials] 2025 Jan 29; Vol. 26 (1), pp. 31. Date of Electronic Publication: 2025 Jan 29.Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Statistical Fragility of Findings From Randomized Phase 3 Trials in Pediatric Oncology.

Authors : Olsen HE; Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.; Kao PC

Subjects: Clinical Trials, Phase III as Topic* ; Randomized Controlled Trials as Topic*/Randomized Controlled Trials as Topic*/Randomized Controlled Trials as Topic*/statistics & numerical data ; Neoplasms*/Neoplasms*/Neoplasms*/therapy

Source: Cancer medicine [Cancer Med] 2024 Dec; Vol. 13 (24), pp. e70356.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

SMILE-stereotactic multiple fraction radiotherapy for non-spine bone metastases: study protocol for a multicenter, open-label phase III randomized controlled trial.

Authors : Foerster R; Department of Radiation Oncology, Cantonal Hospital Winterthur, Winterthur, Switzerland. .; Department of Radiation Oncology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland. .

Subjects: Radiosurgery*/Radiosurgery*/Radiosurgery*/methods ; Radiosurgery*/Radiosurgery*/Radiosurgery*/adverse effects ; Bone Neoplasms*/Bone Neoplasms*/Bone Neoplasms*/secondary

Source: Trials [Trials] 2024 Nov 13; Vol. 25 (1), pp. 762. Date of Electronic Publication: 2024 Nov 13.Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Analysis of innovative two-stage seamless adaptive design with different endpoints and population shift.

Authors : Mai W; Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.; Chow SC

Subjects: Endpoint Determination*/Endpoint Determination*/Endpoint Determination*/statistics & numerical data ; Endpoint Determination*/Endpoint Determination*/Endpoint Determination*/methods ; Clinical Trials, Phase III as Topic*/Clinical Trials, Phase III as Topic*/Clinical Trials, Phase III as Topic*/statistics & numerical data

Source: Journal of biopharmaceutical statistics [J Biopharm Stat] 2024 Oct; Vol. 34 (6), pp. 993-1006. Date of Electronic Publication: 2024 Mar 21.Publisher: Taylor & Francis Country of Publication: England NLM ID: 9200436 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Inclusion of phase III clinical trial costs in health economic evaluations.

Authors : Gandjour A; Frankfurt School of Finance & Management, Adickesallee 32-34, Frankfurt am Main, 60322, Germany. .

Subjects: Clinical Trials, Phase III as Topic* ; Cost-Benefit Analysis*/Cost-Benefit Analysis*/Cost-Benefit Analysis*/methods; Humans

Source: BMC health services research [BMC Health Serv Res] 2024 Oct 01; Vol. 24 (1), pp. 1158. Date of Electronic Publication: 2024 Oct 01.Publisher: BioMed Central Country of Publication: England NLM ID: 101088677 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6963

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Do beta-amyloid-targeted interventions improve cognition, physical functioning, and overt behaviour of Alzheimer's Disease (AD) patients: Protocol for meta-analysis of Phase 3 clinical trials both completed and terminated.

Authors : Stellick Bedrejo CA; Department of Psychiatry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.; Greenshaw A

Subjects: Alzheimer Disease*/Alzheimer Disease*/Alzheimer Disease*/drug therapy ; Alzheimer Disease*/Alzheimer Disease*/Alzheimer Disease*/metabolism ; Amyloid beta-Peptides*/Amyloid beta-Peptides*/Amyloid beta-Peptides*/antagonists & inhibitors

Source: PloS one [PLoS One] 2024 Sep 27; Vol. 19 (9), pp. e0307761. Date of Electronic Publication: 2024 Sep 27 (Print Publication: 2024).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Rapid normalization of vitamin D deficiency in PICU (VITdALIZE-KIDS): study protocol for a phase III, multicenter randomized controlled trial.

Authors : O'Hearn K; Menon K ...

Subjects: Critical Illness* ; Vitamin D Deficiency*/Vitamin D Deficiency*/Vitamin D Deficiency*/drug therapy ; Vitamin D Deficiency*/Vitamin D Deficiency*/Vitamin D Deficiency*/blood

Source: Trials [Trials] 2024 Sep 19; Vol. 25 (1), pp. 619. Date of Electronic Publication: 2024 Sep 19.Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Drug-resistant tuberculosis treatments, the case for a phase III platform trial.

Authors : Yates TA; Barnes S ...

Subjects: Tuberculosis, Multidrug-Resistant*/Tuberculosis, Multidrug-Resistant*/Tuberculosis, Multidrug-Resistant*/drug therapy ; Antitubercular Agents*/Antitubercular Agents*/Antitubercular Agents*/therapeutic use ; Clinical Trials, Phase III as Topic*

Source: Bulletin of the World Health Organization [Bull World Health Organ] 2024 Sep 01; Vol. 102 (9), pp. 657-664.Publisher: World Health Organization Country of Publication: Switzerland NLM ID: 7507052 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial.

Authors : McKetin R; National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia. .; Degan TJ

Subjects: Mirtazapine*/Mirtazapine*/Mirtazapine*/therapeutic use ; Amphetamine-Related Disorders*/Amphetamine-Related Disorders*/Amphetamine-Related Disorders*/drug therapy ; Amphetamine-Related Disorders*/Amphetamine-Related Disorders*/Amphetamine-Related Disorders*/psychology

Source: Trials [Trials] 2024 Jun 22; Vol. 25 (1), pp. 408. Date of Electronic Publication: 2024 Jun 22.Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Non-invasive physical plasma for preventing radiation dermatitis in breast cancer: study protocol for a phase 3 randomised double-blind placebo-controlled trial (NIPP-RD III).

TAD-SIE: sample size estimation for clinical randomized controlled trials using a Trend-Adaptive Design with a Synthetic-Intervention-Based Estimator.

Statistical Fragility of Findings From Randomized Phase 3 Trials in Pediatric Oncology.

SMILE-stereotactic multiple fraction radiotherapy for non-spine bone metastases: study protocol for a multicenter, open-label phase III randomized controlled trial.

Analysis of innovative two-stage seamless adaptive design with different endpoints and population shift.

Inclusion of phase III clinical trial costs in health economic evaluations.

Do beta-amyloid-targeted interventions improve cognition, physical functioning, and overt behaviour of Alzheimer's Disease (AD) patients: Protocol for meta-analysis of Phase 3 clinical trials both completed and terminated.

Rapid normalization of vitamin D deficiency in PICU (VITdALIZE-KIDS): study protocol for a phase III, multicenter randomized controlled trial.

Drug-resistant tuberculosis treatments, the case for a phase III platform trial.

A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial.

اتصل بنا

اتبع